#### An individualized Bayesian method for estimating genomic variants of hypertension

- Md. Asad Rahman<sup>1</sup>, Chunhui Cai<sup>2</sup>, Dennis M. McNamara<sup>3</sup>, Ying Ding<sup>4</sup>, Gregory F. Cooper<sup>2</sup>,
- Xinghua Lu<sup>2</sup>, Jinling Liu<sup>1,5\*</sup>
- <sup>1</sup>Department of Engineering Management and Systems Engineering, Missouri University of
- Science and Technology, Rolla, MO, USA, <sup>2</sup>Department of Biomedical Informatics,
- University of Pittsburgh, Pittsburgh, PA, USA, <sup>3</sup>Department of Medicine, University of
- Pittsburgh, Pittsburgh, PA, USA, <sup>4</sup>Department of Biostatistics, University of Pittsburgh,
- Pittsburgh, PA, USA, <sup>5</sup>Department of Biological Sciences, Missouri University of Science and
- Technology, Rolla, MO, USA,

- \*Corresponding author email: jinling.liu@mst.edu

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

### 24 Abstract

### 25 Background

26 Genomic variants of disease are often discovered nowadays through population-27 based genome-wide association studies (GWAS). Identifying genomic variations potentially 28 underlying a phenotype, such as hypertension, in an individual is important for designing 29 personalized treatment; however, population-level models, such as GWAS, may not capture 30 all of the important, individualized factors well. In addition, GWAS typically requires a large 31 sample size to detect association of low-frequency genomic variants with sufficient power. 32 Here, we report an individualized Bayesian inference (IBI) algorithm for estimating the 33 genomic variants that influence complex traits such as hypertension at the level of an 34 individual (e.g., a patient). By modeling at the level of the individual, IBI seeks to find 35 genomic variants observed in the individual's genome that provide a strong explanation of the phenotype observed in this individual. 36

### 37 Results

38 We applied the IBI algorithm to the data from the Framingham Heart Study to explore 39 genomic influences of hypertension. Among the top-ranking variants identified by IBI and 40 GWAS, there is a significant number of shared variants (intersection); the unique variants identified only by IBI tend to have relatively lower minor allele frequency than those identified 41 42 by GWAS. In addition, we observed that IBI discovered more individualized and diverse 43 variants that explain the hypertension patients better than did GWAS. Furthermore, IBI found 44 several well-known low-frequency variants as well as genes related to blood pressure that 45 were missed by GWAS in the same cohort. Finally, IBI identified top-ranked variants that 46 predicted hypertension better than did GWAS, according to the area under the ROC curve.

### 47 Conclusions

- 49 GWAS especially in detecting low-frequency genomic variants as well as learning
- 50 personalized genomic variants of clinical traits and disease, such as the complex trait of
- 51 hypertension, to help advance precision medicine.

# 52 Keywords

- 53 individualized Bayesian inference, genome-wide association studies, genomic variants,
- 54 single nucleotide polymorphism, hypertension, blood pressure, precision medicine
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66

### 67 Background

68 Hypertension (HTN) is a key risk factor for many cardiovascular diseases, and it was primarily responsible for about 7.8 million world-wide deaths in 2015 alone. Previous studies 69 70 indicate that in addition to environmental factors, genomic factors play a significant role in 71 blood pressure (BP) regulation [1]. Hypertension is a polygenic disease [2] burdening a large 72 population across the globe. Current efforts at identifying significant genomic variants mostly 73 involve the use of genome-wide association studies (GWAS). Although GWAS has 74 successfully identified more than 1000 significant single nucleotide polymorphisms (SNPs: 75 the most common type of genomic variants among people) for BP [3], there are limitations to 76 this commonly used approach. In general, GWAS requires a large cohort to gain enough 77 power to identify the significant SNPs, especially the ones with low minor allele frequency 78 (MAF). That is why before 2015 there were only about 64 significant SNPs identified for 79 blood pressure, and only recently were more SNPs identified due to the increased sample 80 sizes (~ 1 million individuals) [4-6]. Still, most of the SNPs identified so far are common 81 SNPs with small effect sizes, and the total genetic variance in blood pressure explained by 82 these ~1000 SNPs is small (~5.7%) [3]. It is likely that there are a significant number of non-83 common variants missed by GWAS that can help explain much of the remaining genomic 84 variance [7].

GWAS is a population-based approach, and it extracts significant SNPs from a population level, not considering the specific genome of a given individual. Therefore, GWAS is not tailored to identify the genomic influences of HTN in an individual, which is the focus of personalized medicine. It is not uncommon that a HTN patient does not have any of the significant variants identified at the population level. Thus, identifying the most probable genomic variants of individual patients is important but remains an unmet need.

We have developed an individualized Bayesian inference (IBI) algorithm for
estimating the genomic factors influencing the development of hypertension and other
complex traits in a given individual. As a general machine learning framework, IBI applies a

94 Bayesian method to identify the significant genomic variants in a given individual or patient. 95 Bayesian methods including Bayesian multiple logistic [8] or linear regression have been 96 used for identifying the causal SNPs among the significant genomic regions identified by GWAS (i.e., fine mapping) [9, 10]. However, none of these are individualized. IBI evolved 97 98 from a tumor-specific causal inference algorithm (TCI) that members of our team developed for estimating the somatic mutations driving the development of individual cancerous tumors 99 100 [11]. In contrast to TCI, IBI is designed to model and learn the relationships between an 101 individual genome and a complex trait, such as HTN. Also, IBI was optimized for efficient 102 computation with whole-genome data, whereas TCI was developed to use whole-exome 103 data.

104 IBI identifies significant and potentially causal genomic variants for each individual 105 based on his or her specific genomic background (and available training data on many 106 similar individuals). By concentrating on the genomic variants observed in a particular 107 individual, IBI has the potential to discover significant variants of low frequency that exist 108 only in a small number of individuals and could have been missed by GWAS. The genomic 109 variants identified being significant by IBI could help inform the design of personalized 110 treatment for individuals with or at-risk for hypertension.

### 111 Methods

### 112 **Overview of Bayesian Networks.**

A Bayesian network (BN) [12, 13] is a probabilistic graphical model which has two components. One is a graphical structure containing nodes and directed edges. Nodes represent domain variables such as genomic variants or clinical traits. Directed edges represent conditional dependencies between variables. The other component of a BN is a set of parameters which are conditional probabilities. Basically, each node has a conditional probability given its potential causes, which can be described by a conditional probability function. The joint probabilities of all nodes can be written as a product of each node's conditional probability given its direct causes, based on the local causal Markov condition. A
BN is a flexible framework for modeling the probabilistic relationships among variables in a
complex domain via representing the joint probability of all the variables modeled in a
probabilistic structure. A bipartite BN is a particular class of BN with less complexity, where
there are only two sets of nodes in level 1 and level 2, and potential causal relationships only
occur from nodes in level 1 to nodes in level 2.

How do we search for the most probable BN given data? A very popular class of methods are score-based algorithms that assign a Bayesian score to the BN model and return the BN with the highest score [12, 13]. This Bayesian score of the BN model is assigned based on how well this BN is supported by both the data and prior knowledge [14]. In this study, we will use a popular Bayesian score for modeling discrete variables, the Bayesian Dirichlet equivalent uniform (BDeu) score [14] as TCI did [11].

### 132 The general framework of individualized Bayesian inference.

133 As mentioned, IBI is based on TCI [11] and has been further developed and adapted 134 to fit the circumstances of modeling a variety of complex diseases or traits and whole-135 genome genotyping or sequencing data. IBI is designed to estimate the significant genomic 136 variants, such as SNPs, in a specific individual or patient for downstream clinical and 137 molecular phenotypes. IBI uses a bipartite BN [12, 13] for modeling the conditional-138 dependency or predictive relationships between the genomic variants as a set of V nodes 139 and the downstream traits or phenotypes as set of T nodes; directed edges between V and 140 T nodes represent the probabilistic or predictive relationships from variants to traits (Figure 141 1A). Within this bipartite BN, among all the variants in one individual, IBI assigns a posterior 142 probability for each variant (represented by an V node) in influencing or predicting the trait of 143 interest (represented by node T) specific for this individual (Figure 1A, D).

144 For a current individual h, let  $V_s$  be a variable that represents a specific genomic variant s (e.g., a SNP) and let  $T_i$  be a specific trait *i* (e.g., HTN) of this individual. Let  $V_S^h$  be a 145 146 vector representing all the genomic variants in individual h. We will examine the predictive 147 relationship  $(V_s \rightarrow T_i)$  in this individual for each possible  $V_s$ . Let  $P(V_s \rightarrow T_i)$  be the prior probability for  $V_s$  predicting or influencing  $T_i$ , which could be estimated using biological 148 149 background knowledge or could be set using a uniform prior that assumes all the genomic 150 variants have the same prior probability of predicting or influencing  $T_i$ . Let D be the training 151 data without inclusion of individual h. Let  $M_s$  represent the log form of the marginal likelihood 152 of  $P(D | V_s \rightarrow T_i)$  that was derived by assuming one genomic variant s as the potential 153 predictor for the entire population D;  $M_s$  can be further normalized by the summation of  $M_{sr}$ across all the SNPs to derive the posterior probability (PP). When scoring  $V_s \rightarrow T_i$  for the 154 155 entire population D (i.e., it is not individualized) using Bayesian learning and a uniform prior, PP is proportional to  $M_s$ ; thus, the ranking of the specific driver  $V_s$  by  $M_s$  or PP as a potential 156 157 predictor of a trait at the population level is the same. Thus, we will use  $M_s$  as the score for  $V_{\rm s} \rightarrow T_i$ . When evaluating the effect of  $V_{\rm s}$  on  $T_i$  in the entire population using GWAS, the p-158 value is derived to indicate the significance of the association between  $V_s$  and  $T_i$  (Figure 1B). 159

160 IBI partitions the overall population into two subpopulations (Figure 1C). Suppose the current patient has  $V_s = 1$ , which represents the minor-allele of this SNP. Let  $D^{V_s=1}$  represent 161 162 the patient-like-me subpopulation, where all the patients in this subpopulation contain the value  $V_s = 1$ . IBI evaluates how well  $V_s$  predicts the HTN status within  $D^{V_s=1}$ , which has a 163 marginal likelihood score of  $P(D^{V_s=1}|V_s \rightarrow T_i)$  that we abbreviate as  $M_s^1$  (Figure 1C, D). Let 164  $D^{V_s=0}$  represent the remaining cases that do not have  $V_s = 1$ , but rather, have  $V_s = 0$ . To 165 166 predict the data in  $D^{V_s=0}$ , IBI finds the SNP  $V_r$  (where "r" denotes the remaining cases) that maximizes the marginal likelihood of  $V_r \to T_i$ , namely,  $P(D^{V_s=0}|V_r \to T_i)$ , which we abbreviate 167 as  $M_r^0$ . The marginal likelihood for all of the data, given  $V_s$  as an individualized predictor and 168 169  $V_r$  as the best predictor of the remaining cases, is  $M_s^1 + M_r^0$ , which we refer to as  $M_{s,r}$ 

170 (Figure 1C, D). This score of  $M_{s,r}$  can be used to evaluate and rank the capability of  $V_s$  in 171 explaining the patients-like-me subpopulation that contain this minor allele as well as in 172 helping reduce the noises for the remaining subpopulation.

The marginal likelihood is computed using the BDeu score [14] (Figure 1C, D; refer 173 to the TCI paper [8]). Individualized posterior probabilities of the form  $V_s \rightarrow T_i$  are further 174 175 derived relative to the SNPs that are minor alleles in the genome of the current patient h. 176 Thus, the posterior probability takes into consideration the specific genomic background of 177 the given individual (Figure 1D, Equation 2). In summary, IBI is individualized in the following 178 ways: (1) The overall marginal likelihood for each arc  $V_s \rightarrow T_i$  (Equation 1) contains an 179 individualized component that uses the subpopulation of "patients like me" that have the 180 same variant (i.e.,  $V_s = 1$ ). (2) Each individual has a unique set of genomic variants. 181 Depending on the specific set of variants, the posterior probability for the same arc of  $V_s \rightarrow T_i$ may be different in different individuals (Equation 2). The individualized nature of IBI makes 182 183 it a potential tool for advancing precision medicine where personalized treatments are 184 desired for individuals of varying genetic backgrounds. IBI is implemented in python with 185 vectorization and matrix operations for efficient computation involving millions of variants, 186 and has been tested on whole genome sequencing data on the BioData Catalyst platform 187 [15].

# 188 Genome-Wide Association Studies.

GWAS is the standard approach for identifying the significant variants associated with traits at the population level (e.g., p-value  $< 5 \times 10^{-8}$  for genome wide significance). Conventional GWAS uses standard logistic regression models or Fisher's exact test for discrete traits [16]. We performed GWAS using Fisher's exact test on the same datasets to which we applied IBI and compared results.

# 194 Data and data preprocessing.

We used the whole genome genotyping data of Affymetrix HuGeneFocused50K from
the Framingham Heart Study (FHS) cohort (dbGaP Study Accession: phs000007.v30.p11),

197 which covered about 50K gene-centric and coding SNPs across the genome [17, 18]. We 198 used the following functions from plink for further filtration and quality control, and have 199 acquired 38,342 SNPs: --mind 0.03 --geno 0.03 --maf 0.01 -hwe 10e-6 -me 0.05 0.1 -200 sexCheck. We filled missing SNP values with the most frequent value for that particular SNP 201 across the entire population. Dominant coding was then performed in plink, and thus, the 202 final SNP values are 0 or 1 where 0 represents zero copy of the minor allele (risk allele) and 203 1 represents one or two copies of the minor allele. The focus of this paper is to predict the 204 risk (minor) allele SNPs that influence hypertension (high blood pressure) rather than 205 protecting the subject from hypertension. Therefore, we further removed the SNPs that have 206 risk ratio smaller than 1 resulting in a total of 19,276 SNPs of interest.

207 Clinical phenotype data included harmonized systolic BP (SBP) and diastolic BP (DBP) data which were downloaded from PIC-SURE on the NHLBI BioData Catalyst 208 209 platform [15]. SBP and DBP are specifically harmonized by the Trans-omics for Precision 210 Medicine (TOPMed) Data Coordinating Center [19] by taking the average of two SBP or DBP measurements obtained at a single clinic visit. 10 and 5mm Hg were specifically added 211 212 for SBP and DBP for individuals who were taking antihypertensive drugs [20]. If SBP>=140, 213 or DBP>=90 or an individual who was taking antihypertensive drugs, we considered this 214 individual as having HTN and assigned 'HTN = 1'; otherwise, we classified this individual as 215 not having HTN, and we assigned 'HTN = 0'. After merging the SNP data and BP data, we 216 obtained a total of 6,613 patients with 19,276 SNPs. We performed a stratified random split 217 to produce an 80% training set (5,290 subjects) and a 20% test set (1,323 subjects), and we 218 reserved this test set for the prediction task.

219 Results

To evaluate IBI in inferring significant genomic variants for HTN, we compared its performance to that of GWAS. As a proof of concept, we applied both IBI and GWAS to the whole genome data of Affymetrix HuGeneFocused50K measurements and harmonized phenome data of BP measurements from the FHS cohort [18] as described above.

### A Bayesian method for GWAS analysis.

225 As was explained in the Methods section, when using a Bayesian method and a 226 uniform prior to study a single variant's effect on HTN in the population level, the derived  $M_s$ for this variant is proportional to its global posterior probability (GPP), making it possible to 227 228 use the marginal likelihood to find the top predicting SNP (Figure 2A). We observed that 229 when using a uniform prior, as we did in this study, a population-based (i.e., not 230 individualized) Bayesian approach to identifying top-ranked SNPs based on M<sub>s</sub> yielded 231 similar results to the population-based GWAS method (Figure 2A). The Spearman 232 correlation coefficient between the p-value and  $M_s$  across all the 19,276 SNPs is -0.9. We 233 further examined and compared the top 189 SNPs ranked by  $M_s$  or p-value. The top SNPs 234 identified by high  $M_s$  values or low p-values are highly overlapping: 164 out of the top 189 235 SNPs and 18 out of the top 20 SNPs overlapped between these two rankings (Figure 2). 236 Furthermore, the ranking of these top SNPs by  $M_s$  and p-value are either exactly the same 237 or very similar where  $M_s$  is negatively correlated with p-value (Figure 2). 238 IBI complements GWAS and better detects significant variants of low MAF. 239 We applied both IBI and GWAS to the training (discovery) subset of 5,290 FHS 240 subjects with 19,276 SNPs and HTN status, and derived the IBI marginal values of  $M_{s,r}$ 241 (Figure 3A) and GWAS p-values (Figure 3B) for all the SNPs in the Manhattan plots. In 242 Figure 3A, the values of  $M_{s,r}$  were normalized with  $(-2436 - M_{s,r}) / (-2436 - (-2463))$ 243 considering -2436 as the maximum and -2463 as the minimum, based on the min-max 244 normalization technique. For the GWAS analysis, if considering 0.05 / 19276 = 2.59e-6 as 245 the significance level for p-value after the Bonferroni correction, five SNPs reach such 246 significance (Figure 3B). In Figure 2, the population-level  $M_s$  values were derived by assuming one SNP as the global predictor or potential cause of HTN for the entire 247 248 population (Figure 1B). When using two SNPs to specifically explain HTN status from two 249 distinct subpopulations as is done by IBI (Figure 1C), the overall marginal values  $(M_{s,r})$ significantly increase for many SNPs of V<sub>s</sub>. Among all the SNPs, 189 V<sub>s</sub> SNPs have 250

251  $M_{s,r}$  values bigger than the biggest  $M_s$  value derived in the population level from the best 252 global predictor, represented as  $V_a$  (Figure 3A). The higher score of IBI compared to the 253 population-based Bayesian method also has theoretical support. It has been proved that 254 instance-based (i.e., individualized) causal inference methods, a family of algorithms to 255 which the IBI belongs, are consistent. More specifically, in the large sample limit, the score 256 of the data-generating instance-specific model will be assigned the highest score of any model [21]. These results support that the HTN status in the overall population has been 257 258 explained better by IBI with any of the top 189 SNPs,  $V_s$ , explaining the subpopulation of 259  $D^{V_s=1}$  and with the remaining population predictor,  $V_r$ , explaining the remaining  $D^{V_s=0}$ 260 subpopulation, in comparison to using the best global predictor  $V_a$  itself to explain the entire 261 population of D.

262 We performed another evaluation from the perspective of information theory. In this 263 setting, GWAS analysis is searching for a variant  $V_{\rm s}$  that has strong information with respect 264 to a trait  $T_i$  (HTN), and the amount of information can be measured as information gain (IG) 265 [22]. IG can be calculated by splitting samples according to one variable ( $V_{\rm s}$ ) and then 266 measuring the change in the entropy of the other variable  $(T_i)$  during partitions. Rather than 267 focusing on just one variant as in a GWAS analysis, the IBI algorithm evaluates how much 268 information we can gain with respect to the trait  $T_i$  (HTN) if we consider both the specific 269 variant of interest ( $V_s$ ) and the remaining-population predictor ( $V_r$ ), IG ( $V_s, V_r; T_i$ ) [23]. The 270 more  $V_s$  and  $V_r$  complement each other (e.g., they are two distinct predictors for different 271 subgroups) to provide information with respect to  $T_i$ , the higher the IG. In other words, IBI 272 searches for variants that not only explain HTN well in the "patients-like-me" subpopulation, 273 but also help enhance the information of  $V_r$  with respect to HTN in the remaining 274 subpopulation that do not contain this specific variant of interest. Actually, the ranking of the 275 top 189 SNPs by IBI  $M_{s,r}$  turned out to be highly correlated (Spearman correlation coefficient, r = 0.9) to their ranking by IG values: in general, the higher the  $M_{s,r}$ , the higher 276 277 the IG. Based on information gain values, top-5 IBI SNPs were rs11574358, rs1794108,

278 rs11000217, rs2292664 and rs9928967 while top-5 GWAS SNPs were rs11574358,

rs2292664, rs383306, rs5491 and rs1794108. IG values for the top 189 IBI SNPs of  $V_s$ selected by  $M_{s,r}$  are significantly higher than those of the top 189 GWAS SNPs selected by the p-values; IG values for the top 189 GWAS SNPs are also significantly higher than the values for 189 randomly-selected SNPs (Figure 3C) as expected.

283 We further examined whether there is any overlap between the top 189 IBI and 284 GWAS SNPs. We found that 41 of the top 189 SNPs were identified by both IBI and GWAS 285 (Figure 3D), and 3 of the top 5 IBI and GWAS SNPs are the same (Figure 3A, B). Thus, IBI 286 and GWAS share many of the same top SNPs, suggesting a mutual agreement between 287 these two approaches. The unique SNPs for IBI or GWAS support that the two approaches 288 are also complementary (Fig. 3D). We further examined the MAF distribution for the different 289 subsets in Figure 3D (Figure 3E). Interestingly, the IBI-only SNPs overall had much lower 290 MAF than GWAS-only SNPs (Fig. 3E). This result provides support for the hypothesis that 291 IBI is more capable of identifying lower-frequency significant variants, relative to GWAS, by 292 concentrating on the genomic variants of a given individual in a specific subpopulation.

# IBI discovered more individualized and diverse significant SNPs that better explain the HTN patients, compared to GWAS.

295 For a given individual *h*, IBI derives the posterior probability for each genomic variant 296  $V_s$ ,  $P(V_s^h \to T_i^h | D)$ , by normalizing  $M_{s,r}$  with a summation of all the  $M_{s,r}$  across all the existing 297 minor allele SNPs (i.e., the SNP value is 1) in this individual. This posterior probability takes 298 into consideration the diverse genomic background or context for different individuals. More 299 specifically, a particular SNP  $V_s$  with the same  $M_{s,r}$  may have different posterior probabilities 300 in different individuals due to their distinct genomic background (i.e., different sets of existing 301 minor allele SNPs). For a given HTN patient, IBI ranked all the minor alleles existing in this 302 individual based on their individualized posterior probabilities (this ranking will be the same 303 as the ranking based on  $M_{s,r}$  in a given patient); the SNP with the highest posterior 304 probability was considered as the most probable influence of HTN for this given patient. For

comparison, we designated a top SNP for each HTN patient based on the population-level
p-values derived by GWAS: among the existing minor alleles in a given HTN patient, the
non-protective minor allele with the lowest (most significant) p-value was considered to be
the most probable influence for HTN in this particular patient.

309 Among all the 930 HTN patients in the discovery dataset, we identified 16 unique 310 SNPs according to GWAS ranking (Figure 4A) and 25 unique SNPs based on IBI ranking 311 (Figure 4B); each of these unique SNPs was assigned by GWAS or IBI as a top-1 SNP for at 312 least one HTN patient. The number of HTN patients explained by each of these unique SNP 313 can be derived by the differences of the accumulated number of explained HTN patients 314 showed in Figure 4A, B. The more unique SNPs identified by IBI suggested IBI was able to 315 find a more diverse set of significant SNPs with a more personalized approach. IBI identified 316 13 SNPs that explain less than 10 HTN patients individually while GWAS found 6 such SNPs. Interestingly, at the same time, IBI assigns the intronic SNP 'rs13265032' in the 317 CSMD1 loci as the top-1 SNP with the highest PP or  $M_{s,r}$  for each of the 425 (46%) of HTN 318 319 patients (Figure 4B).

For the GWAS analysis, if considering 0.05/19276 = 2.59e-6 as the significance level for p-value after the Bonferroni correction, then 120 out of 930 (12.9%) HTN patients can be assigned a significant SNP identified by GWAS; even with a relaxed significance level of 1.09e-5, only 146 out of 930 (15.7%) HTN patients are covered or explained by these significant GWAS SNPs (Figure 4A). This suggests that the significant SNPs of HTN identified at the population level by GWAS do not necessarily exist in a given HTN patient, leaving a significant portion of HTN patients unexplained by these significant SNPs.

327 On average, there are 7,767 out of 19,276 minor allele SNPs existing in the HTN 328 patients. If assuming all these existing risk alleles have the same prior probability in causing 329 HTN, and only one of them is causing HTN, then the prior probability for each risk allele is 330 1.0/7767 = 1.3e-4. Interestingly, the top one SNP selected by IBI for each HTN patient has 331 much higher posterior probability ranging from 0.08 to 0.99 (Figure 4C). If considering 0.1 as

- a significant posterior probability threshold, then 922 out of 930 (99.1%) HTN patients can
  be assigned a significant IBI SNP as the potential cause for their HTN status; with a more
  restrictive threshold of 0.2, 741 out of 930 (79.7%) HTN patients can be explained. These
  results suggested that IBI was able to find a top SNP with significant posterior probability
  (>=0.1), relative to the random chance (1.3e-4), for the majority of HTN patients as a
  potential genomic cause.
- so, potential generation outdot.

# 338Table 1. Novel SNPs in BP-associated genes identified by IBI as the individualized and

339

### most-probable HTN cause

rs ID	Genes: Variant type	MAF	IBI	GWAS	p-	# HTN
			rank	rank	value	explained
rs13265032	CSMD1: Intron Variant	0.34	12	5361	0.26	425
rs1564573	CSMD1: Intron Variant	0.42	20	1858	0.08	27
rs2449184	CSMD1: Intron Variant	0.42	33	3760	0.17	0
rs1803274	BCHE: Missense Variant	0.20	23	221	0.01	9
rs948028	GRIK4: Intron Variant	0.16	38	14922	0.78	2
rs12779623	MALRD1: Missense Variant	0.20	48	303	0.01	1

340 As is shown in Table 1, the intronic SNP 'rs13265032' in the CSMD1 loci that was 341 assigned as the top-1 SNP by IBI for 46% (425) of HTN patients, was also ranked high (12) 342 by IBI M<sub>s r</sub> among all the SNPs. By contrast, this SNP was never assigned as a top-1 SNP for any HTN patient by GWAS and this SNP was ranked very low (5361) by GWAS among 343 344 all the SNPs. Interestingly, other intronic SNPs in the CSMD1 loci have been reported to be 345 associated with hypertension [24] or blood pressure response to hydrochlorothiazide [25, 346 26], an antihypertensive drug. Among all the 86 SNPs located in the CSMD1 loci in our 347 dataset, three of them were ranked very high by IBI as is shown in Table 1, while all of them 348 were ranked relatively low by GWAS. These three novel SNPs identified by IBI in the CSMD1 loci provide evidence to support the reported role of CSMD1 in HTN, which 349 350 themselves may warrant further analysis for their potential causal influence on CSMD1

351	regulation. In addition to SNPs in the CSMD1 loci, IBI also identified a novel missense
352	variant of 'rs1803274' in the BCHE loci, a novel intron variant of 'rs948028' in the GRIK4 loci
353	and a novel missense variant of 'rs12779623' in the MALRD1 loci as top-1 likely cause of
354	HTN in 9, 2 and 1 HTN patient, respectively (Table 1). Interestingly, BCHE [27, 28] loci,
355	GRIK4 [29] loci and MALRD1 loci [4] have been reported to be associated with blood
356	pressure regulation, although GWAS analysis ranked their SNPs relatively low (Table 1).
357	Overall, these results provide support for IBI being able to identify novel and biologically
358	meaningful SNPs or genes associated with HTN that were missed by GWAS analysis.
359	IBI found well-known significant variants or genes that were missed by the parallel
360	GWAS analysis in the same cohort.
361	We list several missense variants (Table 2) as well as the gene loci (Table 3) that
362	were previously reported for their influence on blood pressure regulation, in addition to the

363 ones discussed in Table 1. In Tables 2 and 3, IBI ranks were determined by  $M_{s,r}$  while

364 GWAS ranks were determined by the p-value.

# Table 2. SNPs well-known for blood pressure regulation identified by IBI but missed by GWAS.

rs ID	Genes: Variant type	MAF	IBI rank	GWAS rank	p-value
rs11575542	DDC: Missense Variant	0.01	79	599	0.02
rs37369	AGXT2: Missense Variant	0.08	93	748	0.03
				_	
rs723580	CLIC5: Missense Variant	0.04	189	11851	0.61

In Table 2, the missense variant of rs37369 [30] has been shown to be one of the 4
functional SNPs of AGXT2, which has been reported to have strong associations with
several cardiorenal traits, such as coronary heart disease [31]. Its significant association with
hypertension was very recently reported via multiple regression analysis involving only
several targeted SNPs [32]. The missense variant rs11575542 was very recently identified
as a functional variant of the DOPA Decarboxylase (*DDC*) gene during the systematic

373 polymorphism screening across the 15-Exon DCC locus [33]. The SNP was shown to alter 374 the enzyme activity of DCC and result in changes in renal DA excretion that is linked to hypertension [33]. The missense variant of rs723580 was reported to be a top trans-eSNP 375 [34] for the expression level of EPO associated with the red blood cell traits that were 376 377 strongly linked to hypertension [35]. Intriguingly, with low MAF in our relatively small discovery cohort, these three SNPs were ranked much higher by IBI than by the parallel 378 GWAS analysis (Table 2). This result provides support that IBI can recognize biologically 379 380 meaningful genomic variants of low MAF, relative to GWAS, particularly when the sample 381 size is small compared to the number of SNPs to be tested.

# 382 Table 3. Genes well-known for blood pressure regulation identified by IBI but ranked

383

# relatively low by GWAS.

					Тор	
rs ID	Conos: Variant typo		IBI	GWAS	GW	n-value
	Conco. vanant type		rank	rank	AS	p-value
					rank	
rs3211938	CD36 [36, 37]: Stop Gained	0.01	32	141	141	3.8E-03
rs6730396	ALLC [38]: Missense Variant	0.01	45	192	192	5.5E-03
rs9896904	ANKFN1 [39]: Intron Variant	0.07	57	14392	2130	7.5E-01
rs11899922	THSD7B [4, 40]: Intron Variant	0.07	70	9415	929	4.8E-01
rs10968668	LINGO2 [41, 42]: Intron Variant	0.08	80	1237	1237	4.9E-02
rs13261739	PDGFRL [43, 44]: Intron Variant	0.13	94	7156	7156	3.6E-01
rs6140644	PLCB1 [45]: Intron Variant	0.17	116	9947	699	5.1E-01
rs7647302	KCNAB1 [46]: Intron Variant	0.01	158	9528	1964	4.9E-01

384

Table 3 shows a list of genes that have been reported to be associated with BP

regulation or HTN where at least one related paper is listed for each gene. IBI identified
these genes as candidate genes influencing HTN since these gene loci contain at least one

novel SNP that is highly ranked by IBI for its association with HTN. Interestingly, all of these

388 genes were ranked relatively low by GWAS even considering the highest SNP rank by 389 GWAS ('Top GWAS rank' in Table 3) within each gene locus; all of these novel SNPs were 390 also ranked relatively low by GWAS ('GWAS rank' in Table 3) with non-significant p-values 391 (Table 3). Moreover, among these eight SNPs highly-ranked by IBI and lowly-ranked by 392 GWAS, six have MAF lower than 0.1 and three have MAF as low as 0.01 (Table 3). This 393 together with Table 2 supports that IBI is more capable in identifying significant variants of 394 low MAF, compared to GWAS.

# 395 IBI top SNPs identify genetic risk scores that are more predictive for HTN than do the 396 GWAS top SNPs.

397 We further compared the capabilities of significant SNPs, identified by IBI and 398 GWAS, in predicting HTN. After running IBI and GWAS on the training (discovery) dataset, 399 we were able to rank all the SNPs based on  $M_{sr}$  derived from IBI or p-values obtained from 400 GWAS. For each subject in the test set, based on IBI ranking or GWAS ranking, we 401 identified the top 1 and 3 SNPs that exist in this subject (with a value of '1' denoting a minor 402 allele). We then used these top SNPs to calculate the genetic risk scores (GRS) for each 403 subject by the sum of his or her risk alleles, weighted by odds ratio for GWAS top SNPs or 404 by  $M_{s,r}$  for IBI top SNPs. We further use min-max normalization to normalize both the IBI 405 and GWAS GRS to avoid potential bias from the different scales of the original values. We 406 then directly calculated the area under ROC curve (AUROC or AUC) using the normalized 407 GRS for each patient (Figure 5). We also trained a logistic regression model for HTN 408 prediction using this feature of normalized GRS, which gave very similar results (data not 409 shown).

As expected, using randomly selected SNPs showed poor prediction performance,
with an AUROC of 0.50 (Figure 5A, D); the GWAS-selected top one or three SNPs both
have an AUROC of 0.55 (Figure 5B, E) suggesting some level of prediction; the IBI-selected
top SNP had an AUROC of 0.59 (Figure 5C) and the top 3 SNPs had an AUROC of 0.60

414 (Figure 5F). The higher AUROC achieved by IBI provides support that the top SNPs it
415 selects predict hypertension better than the top SNPs selected by GWAS.

#### 416 **Discussion**

417 In this study, we developed and applied a novel and individualized method (IBI) to 418 estimate the personalized genomic variants for the complex trait of hypertension. We 419 compared its performance with the population-based GWAS method using a real dataset 420 from the FHS cohort. The significant overlap of the top-ranked SNPs by both IBI and GWAS 421 suggest a degree of agreement of these two approaches. On the other hand, the unique 422 SNPs they found support a complementary role of IBI to current GWAS analyses. 423 Interestingly, by focusing on each individual and its patient-like-me subgroup, IBI was 424 capable of identifying significant SNPs of low MAF in the same cohort, relative to GWAS. IBI 425 was also able to identify more diverse and individualized top SNPs to explain the HTN 426 patients. Moreover, the top SNPs identified by IBI from the discovery cohort were able to 427 predict HTN better than the top ones derived from GWAS when applied to an unseen test 428 cohort. We also identified evidence from the literature to support the biological significance of top SNPs found by IBI, especially the ones highly-ranked by IBI and lowly-ranked by 429 GWAS. In summary, our study provides support that IBI can serve as a complementary 430 431 approach in discovering novel and personalized genomic variants that may be missed by GWAS. 432

Contemporary GWAS studies often involve a large sample size (~1 million) to gain
sufficient power, especially for variants of low MAF. Considering the large genomic
heterogeneity among different individuals, as well as the nature of complex diseases often
being affected by many variants of small effect size, an alternative approach is to focus on
the subpopulation containing the specific variant of low MAF under evaluation, as IBI does.
In this way, IBI may be able to better evaluate the effect of low-MAF variants in a patientlike-me subpopulation, without the potential noise from a large remaining population not

440 containing such variants; moreover, this large remaining population could be explained 441 better with a remaining population driver. The fact that the top-ranked SNPs by IBI in general 442 have a higher overall marginal likelihood,  $M_{sr}$ , and higher information gain with respect to 443 the HTN status, provide support that IBI may have found specific drivers that better explain 444 the subpopulations. Our results also support that IBI is not compromised in identifying 445 significant high-MAF SNPs. IBI's population partition strategy aligns well with the concept of 446 personalized medicine in which different individuals or subpopulations may have different 447 underlying genomic influences on producing complex clinical phenotypes such as HTN.

448 As a general Bayesian framework, IBI can be applied to any discrete trait. It can also 449 be applied to continuous traits by changing the marginal likelihood function from using the 450 BDeu score for discrete variables to using the Bayesian information criterion (BIC) score for 451 continuous variables [14]. For the current approach presented in this study, one limitation is 452 that it only considers the genomic factors of HTN, while not modeling the effects of other 453 factors such as age, sex, population structure and the family relatedness that may exist in 454 this FHS cohort. To model the effects from non-genomic factors, we plan to incorporate 455 linear mixed models [47-51] into our current framework. Also, due to confounding factors 456 such as population structure, as well as linage disequilibrium (LD), the predictive variants 457 described in this paper are not guaranteed to be causal. Further fine mapping approaches, 458 functional analysis, or Mendelian randomization can be used to further pinpoint the potential 459 causality. Another interesting future direction is to search for more than one genomic variant 460 that might work together to affect and predict the phenotypes of individuals and 461 subpopulations.

### 462 Conclusions

In summary, we described a novel Bayesian method for identifying personalized
genomic variants that predict complex traits, such as HTN. IBI can serve as a
complementary approach to GWAS, especially in detecting significant genomic variants of

- 466 low frequency. The novel SNPs we identified for HTN warrant further analysis for their
- 467 possible causal role in blood pressure regulation.

### 468 List of abbreviations

- 469 GWAS: Genome Wide Association Study
- 470 IBI: Individualized Bayesian inference
- 471 TCI: tumor-specific causal inference
- 472 HTN: Hypertension
- 473 BP: Blood pressure
- 474 SBP: Systolic blood pressure
- 475 DBP: Diastolic blood pressure
- 476 FHS: Framingham Heart Study
- 477 MAF: Minor allele frequency
- 478 CBN: Causal Bayesian network
- 479 BDeu: Bayesian Dirichlet equivalent uniform
- 480 TOPMed: The Trans-Omics for Precision Medicine
- 481 IG: Information gain
- 482 GRS: Genetic risk score
- 483 AUROC or AUC: area under ROC curve
- 484 BIC: Bayesian information criterion
- 485 Declarations
- 486 Ethics approval and consent to participate
- 487 Not applicable.
- 488 Consent for publication
- 489 Not applicable.
- 490 Availability of data and materials

- 491 The genomic and blood pressure data from the FHS cohort (study
- 492 accession: phs000007.v30.p11) are publicly available via controlled-access through the
- 493 database of Genotypes and Phenotypes Study
- 494 (https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study\_id=phs000007.v30.p11).
- 495 The source code for IBI is publicly available on GitHub at https://github.com/asadcfc/IBI.

### 496 **Competing interests**

497 The authors declared no competing interests.

### 498 Authors' contributions

499 JL designed and implemented the IBI algorithm in python, conceived and designed the

500 experiments, and wrote the paper; MA.R and JL carried out the data collection, modeling,

analyses; XL and GC provided insightful advices about the design of the IBI algorithm and

some of the experiments, as well as edited the manuscript; YD provided advice for whole-

503 genome data processing and GWAS analysis; DM provided general advice on hypertension

504 development and its potential genomic causes; CC helped with the information gain

505 experiment; All authors read and approved the final manuscript.

# 506 Acknowledgements

507 The Framingham Heart Study, within the database of Genotypes and Phenotypes Study 508 (accession #: phs000007.v30.p11), is conducted and supported by the National Heart, Lung, 509 and Blood Institute (NHLBI) in collaboration with Boston University (Contract No. N01-HC-510 25195 and HHSN268201500001I). This manuscript was not prepared in collaboration with investigators of the Framingham Heart Study and does not necessarily reflect the opinions 511 512 or views of the Framingham Heart Study, Boston University, or NHLBI. Funding for SHARe 513 Affymetrix genotyping was provided by NHLBI Contract N02-HL- 64278. SHARe Illumina 514 genotyping was provided under an agreement between Illumina and Boston University.

- 515 Funding for Affymetrix genotyping of the FHS Omni cohorts was provided by Intramural
- 516 NHLBI funds from Andrew D. Johnson and Christopher J. O'Donnell.
- 517 Support for this work was provided by the National Institutes of Health, National Heart, Lung,
- and Blood Institute, through the BioData Catalyst program (award 10T3HL142479-01,
- 519 1OT3HL142478-01, 1OT3HL142481-01, 1OT3HL142480-01, 1OT3HL147154-01). Any
- 520 opinions expressed in this document are those of the author(s) and do not necessarily reflect
- 521 the views of NHLBI, individual BioData Catalyst team members, or affiliated organizations
- and institutions. The authors wish to acknowledge the contributions of the consortium
- 523 working on the development of the NHLBI BioData Catalyst ecosystem.
- 524

# 525 Funding

- 526 This research was funded in part by the BioData Catalyst Fellowship award (0065304) from
- 527 the National Institutes of Health, National Heart, Lung, and Blood Institute through the
- 528 University of North Carolina at Chapel Hill, grant R01LM012011 from the National Institutes
- of Health, R01 MD009118 from the National Institute on Minority Health and Health
- 530 Disparities (NIMHD).

# 531 References

- 532 1. Padmanabhan S, Joe B: Towards Precision Medicine for Hypertension: A Review of
- Genomic, Epigenomic, and Microbiomic Effects on Blood Pressure in Experimental Rat
  Models and Humans. *Physiol Rev* 2017, 97(4):1469-1528.
- 535 2. Padmanabhan S, Dominiczak AF: Genomics of hypertension: the road to precision
  536 medicine. *Nat Rev Cardiol* 2021, 18(4):235-250.
- 537 3. Cabrera CP, Ng FL, Nicholls HL, Gupta A, Barnes MR, Munroe PB, Caulfield MJ: Over
- 538 1000 genetic loci influencing blood pressure with multiple systems and tissues
- 539 implicated. *Hum Mol Genet* 2019, 28(R2):R151-R161.

540	4.	Evangelou E, Warren HR, Mosen-Ansorena D, Mifsud B, Pazoki R, Gao H, Ntritsos G,
541		Dimou N, Cabrera CP, Karaman I et al: Genetic analysis of over 1 million people
542		identifies 535 new loci associated with blood pressure traits. Nat Genet 2018,
543		50(10):1412-1425.
544	5.	Surendran P, Feofanova EV, Lahrouchi N, Ntalla I, Karthikeyan S, Cook J, Chen L,
545		Mifsud B, Yao C, Kraja AT et al: Discovery of rare variants associated with blood
546		pressure regulation through meta-analysis of 1.3 million individuals. Nat Genet 2020,
547		52(12):1314-1332.
548	6.	Giri A, Hellwege JN, Keaton JM, Park J, Qiu C, Warren HR, Torstenson ES, Kovesdy
549		CP, Sun YV, Wilson OD et al: Trans-ethnic association study of blood pressure
550		determinants in over 750,000 individuals. Nat Genet 2019, 51(1):51-62.
551	7.	Russo A, Di Gaetano C, Cugliari G, Matullo G: Advances in the Genetics of
552		Hypertension: The Effect of Rare Variants. Int J Mol Sci 2018, 19(3).
553	8.	Banerjee S, Zeng L, Schunkert H, Soding J: Bayesian multiple logistic regression for
554		case-control GWAS. PLoS Genet 2018, 14(12):e1007856.
555	9.	Schaid DJ, Chen W, Larson NB: From genome-wide associations to candidate causal
556		variants by statistical fine-mapping. Nat Rev Genet 2018, 19(8):491-504.
557	10.	Stephens M, Balding DJ: Bayesian statistical methods for genetic association studies.
558		Nat Rev Genet 2009, 10(10):681-690.
559	11.	Cai C, Cooper GF, Lu KN, Ma X, Xu S, Zhao Z, Chen X, Xue Y, Lee AV, Clark N et al:
560		Systematic discovery of the functional impact of somatic genome alterations in individual
561		tumors through tumor-specific causal inference. PLoS Comput Biol 2019,
562		15(7):e1007088.
563	12.	Heckerman D, Meek C, Cooper G: A Bayesian approach to causal discovery. In:
564		Computation, causation, and discovery (MIT Press) Edited by Glymour C, Cooper G,
565		vol. 19; 1999: 141-166.

566 13. Spirtes P GC, Scheines R.: Causation, Prediction, and Search.: Cambridge, MA: MIT
567 Press;; 2000.

568	14.	Heckerman D, Geiger D, Chickering DM: Learning Bayesian networks: The combination
569		of knowledge and statistical data. Machine learning 1995, 20(3):197-243.
570	15.	Consortium BC: The NHLBI BioData Catalyst. Zenodo(31 August 2020, date last
571		accessed) 2020.
572	16.	Gogarten SM, Sofer T, Chen H, Yu C, Brody JA, Thornton TA, Rice KM, Conomos MP:
573		Genetic association testing using the GENESIS R/Bioconductor package. Bioinformatics
574		2019, 35(24):5346-5348.
575	17.	Mahmood SS, Levy D, Vasan RS, Wang TJ: The Framingham Heart Study and the
576		epidemiology of cardiovascular disease: a historical perspective. The Lancet 2014,
577		383(9921):999-1008.
578	18.	Tsao CW, Vasan RS: Cohort Profile: The Framingham Heart Study (FHS): overview of
579		milestones in cardiovascular epidemiology. Int J Epidemiol 2015, 44(6):1800-1813.
580	19.	Stilp AM, Emery LS, Broome JG, Buth EJ, Khan AT, Laurie CA, Wang FF, Wong Q,
581		Chen D, D'Augustine CM et al: A System for Phenotype Harmonization in the National
582		Heart, Lung, and Blood Institute Trans-Omics for Precision Medicine (TOPMed)
583		Program. Am J Epidemiol 2021, 190(10):1977-1992.
584	20.	Levy D, Ehret GB, Rice K, Verwoert GC, Launer LJ, Dehghan A, Glazer NL, Morrison
585		AC, Johnson AD, Aspelund T et al: Genome-wide association study of blood pressure
586		and hypertension. <i>Nat Genet</i> 2009, 41(6):677-687.
587	21.	Jabbari F: Instance-Specific Causal Bayesian Network Structure Learning. University of
588		Pittsburgh; 2021.
589	22.	KENT JT: Information gain and a general measure of correlation. Biometrika 1983,
590		70(1):163-173.
591	23.	Quinlan JR: Induction of decision trees. <i>Machine learning</i> 1986, 1(1):81-106.
592	24.	Hong KW, Go MJ, Jin HS, Lim JE, Lee JY, Han BG, Hwang SY, Lee SH, Park HK, Cho
593		YS et al: Genetic variations in ATP2B1, CSK, ARSG and CSMD1 loci are related to
594		blood pressure and/or hypertension in two Korean cohorts. Journal of Human

595 *Hypertension* 2010, 24(6):367-372.

- 596 25. Chittani M, Zaninello R, Lanzani C, Frau F, Ortu MF, Salvi E, Fresu G, Citterio L, Braga
- 597 D, Piras DA et al: TET2 and CSMD1 genes affect SBP response to hydrochlorothiazide
- in never-treated essential hypertensives. *J Hypertens* 2015, 33(6):1301-1309.
- 599 26. Salvi E, Wang Z, Rizzi F, Gong Y, McDonough CW, Padmanabhan S, Hiltunen TP,
- Lanzani C, Zaninello R, Chittani M *et al*: Genome-Wide and Gene-Based Meta-Analyses
- 601 Identify Novel Loci Influencing Blood Pressure Response to Hydrochlorothiazide.
- 602 *Hypertension* 2017, 69(1):51-59.
- 27. Benyamin B, Middelberg RP, Lind PA, Valle AM, Gordon S, Nyholt DR, Medland SE,
- 604 Henders AK, Heath AC, Madden PAF *et al*: GWAS of butyrylcholinesterase activity
- 605 identifies four novel loci, independent effects within BCHE and secondary associations
- 606 with metabolic risk factors. *Human Molecular Genetics* 2011, 20(22):4504-4514.
- 28. Cardoso AM, Abdalla FH, Bagatini MD, Martins CC, Fiorin Fda S, Baldissarelli J, Costa
- 608 P, Mello FF, Fiorenza AM, Serres JD *et al*: Swimming training prevents alterations in
- 609 acetylcholinesterase and butyrylcholinesterase activities in hypertensive rats. *Am J*
- 610 *Hypertens* 2014, 27(4):522-529.
- 611 29. Rutherford S, Cai G, Lopez-Alvarenga JC, Kent JW, Voruganti VS, Proffitt JM, Curran
- 512 JE, Johnson MP, Dyer TD, Jowett JB: A chromosome 11q quantitative-trait locus
- 613 influences change of blood-pressure measurements over time in Mexican Americans of
- the San Antonio Family Heart Study. *The American Journal of Human Genetics* 2007,
- 615 81(4):744-755.
- 30. Suhre K, Wallaschofski H, Raffler J, Friedrich N, Haring R, Michael K, Wasner C, Krebs
- 617 A, Kronenberg F, Chang D: A genome-wide association study of metabolic traits in
- 618 human urine. *Nature genetics* 2011, 43(6):565-569.
- 619 31. Hu XL, Zeng WJ, Li MP, Yang YL, Kuang DB, Li H, Zhang YJ, Jiang C, Peng LM, Qi H
- *et al*: AGXT2 rs37369 polymorphism predicts the renal function in patients with chronic
  heart failure. *Gene* 2017, 637:145-151.
- 32. Yoshino Y, Kumon H, Mori T, Yoshida T, Tachibana A, Shimizu H, Iga J-i, Ueno S-i:
- 623 Effects of AGXT2 variants on blood pressure and blood sugar among 750 older

524 Japanese subjects recruited by the complete enumeration survey method. BMC

625 *Genomics* 2021, 22(1):287.

- 626 33. Miramontes-Gonzalez JP, Hightower CM, Zhang K, Kurosaki H, Schork AJ, Biswas N,
- 627 Vaingankar S, Mahata M, Lipkowitz MS, Nievergelt CM *et al*: A new common functional
- 628 coding variant at the DDC gene change renal enzyme activity and modify renal
- 629 dopamine function. *Scientific Reports* 2019, 9(1):5055.
- 630 34. Zhang X, Johnson AD, Hendricks AE, Hwang S-J, Tanriverdi K, Ganesh SK, Smith NL,
- 631 Peyser PA, Freedman JE, O'Donnell CJ: Genetic associations with expression for
- 632 genes implicated in GWAS studies for atherosclerotic cardiovascular disease and blood

633 phenotypes. *Human Molecular Genetics* 2013, 23(3):782-795.

- 35. Tsuda K: Red blood cell abnormalities and hypertension. *Hypertension Research* 2020,
  43(1):72-73.
- 636 36. Momeni-Moghaddam MA, Asadikaram G, Akbari H, Abolhassani M, Masoumi M,
- 637 Nadimy Z, Khaksari M: CD36 gene polymorphism rs1761667 (G> A) is associated with
- 638 hypertension and coronary artery disease in an Iranian population. *BMC cardiovascular*

639 *disorders* 2019, 19(1):1-9.

- 640 37. Pravenec M, Churchill PC, Churchill MC, Viklicky O, Kazdova L, Aitman TJ, Petretto E,
- 641 Hubner N, Wallace CA, Zimdahl H: Identification of renal Cd36 as a determinant of
- blood pressure and risk for hypertension. *Nature genetics* 2008, 40(8):952-954.
- 643 38. Sung YJ, Basson J, Cheng N, Nguyen K-DH, Nandakumar P, Hunt SC, Arnett DK,
- 644 Dávila-Román VG, Rao DC, Chakravarti A: The role of rare variants in systolic blood
- 645 pressure: analysis of ExomeChip data in HyperGEN African Americans. *Human heredity*
- 646 2015, 79(1):20-27.
- 39. Chittani M, Zaninello R, Lanzani C, Frau F, Ortu MF, Salvi E, Fresu G, Citterio L, Braga
- D, Piras DA: TET2 and CSMD1genes affect SBP response to hydrochlorothiazide in
- 649 never-treated essential hypertensives. *Journal of hypertension* 2015, 33(6):1301.

- 40. de Las Fuentes L, Sung YJ, Schwander KL, Kalathiveetil S, Hunt SC, Arnett DK, Rao D:
- 651 The role of SNP-loop diuretic interactions in hypertension across ethnic groups in
- HyperGEN. Frontiers in genetics 2013, 4:304.
- 41. Parmar PG, Taal HR, Timpson NJ, Thiering E, Lehtimäki T, Marinelli M, Lind PA, Howe
- 654 LD, Verwoert G, Aalto V: International genome-wide association study consortium
- 655 identifies novel loci associated with blood pressure in children and adolescents.
- 656 *Circulation: Cardiovascular Genetics* 2016, 9(3):266-278.
- 42. Feitosa MF, Kraja AT, Chasman DI, Sung YJ, Winkler TW, Ntalla I, Guo X, Franceschini
- 658 N, Cheng C-Y, Sim X: Novel genetic associations for blood pressure identified via gene-
- alcohol interaction in up to 570K individuals across multiple ancestries. *PloS one* 2018,
- 660 13(6):e0198166.
- 43. Yang W, Huang J, Yao C, Fan Z, Ge D, Gan W, Huang G, Hui R, Shen Y, Qiang B:
- 662 Evidence for linkage and association of the markers near the LPL gene with
- hypertension in Chinese families. *Journal of medical genetics* 2003, 40(5):e57-e57.
- 44. Chun HJ, Bonnet S, Chan SY: Translational advances in the field of pulmonary
- 665 hypertension. Translating MicroRNA biology in pulmonary hypertension. It will take more
- than "miR" words. American journal of respiratory and critical care medicine 2017,
- 667 195(2):167-178.
- 45. Warren HR, Evangelou E, Cabrera CP, Gao H, Ren M, Mifsud B, Ntalla I, Surendran P,

Liu C, Cook JP: Genome-wide association analysis identifies novel blood pressure loci
and offers biological insights into cardiovascular risk. *Nature genetics* 2017, 49(3):403-

671 415.

46. McCarthy NS, Vangjeli C, Cavalleri GL, Delanty N, Shianna KV, Surendran P, O'Brien
E, Munroe PB, Masca N, Tomaszewski M: Two further blood pressure loci identified in
ion channel genes with a genecentric approach. *Circulation: Cardiovascular Genetics*2014, 7(6):873-879.

- 47. Chen H, Wang C, Conomos MP, Stilp AM, Li Z, Sofer T, Szpiro AA, Chen W, Brehm JM,
- 677 Celedon JC *et al*: Control for population structure and relatedness for binary traits in

ora genetic association studies via logistic mixed models. Am J Hum Gene	et 2016,
--	----------

679 98(4):653-666.

- 48. Lippert C, Listgarten J, Liu Y, Kadie CM, Davidson RI, Heckerman D: FaST linear mixed
- 681 models for genome-wide association studies. *Nat Methods* 2011, 8(10):833-835.
- 49. Pirinen M, Donnelly P, Spencer CCA: Efficient computation with a linear mixed model on
- 683 large-scale data sets with applications to genetic studies. *The Annals of Applied*
- 684 *Statistics* 2013, 7(1).
- 50. Wen YJ, Zhang H, Ni YL, Huang B, Zhang J, Feng JY, Wang SB, Dunwell JM, Zhang
- 686 YM, Wu R: Methodological implementation of mixed linear models in multi-locus

genome-wide association studies. *Brief Bioinform* 2018, 19(4):700-712.

- 51. Yu J, Pressoir G, Briggs WH, Vroh Bi I, Yamasaki M, Doebley JF, McMullen MD, Gaut
- 689 BS, Nielsen DM, Holland JB *et al*: A unified mixed-model method for association
- 690 mapping that accounts for multiple levels of relatedness. *Nat Genet* 2006, 38(2):203-
- 691

208.

- 692
- 693
- 694
- 695
- 696
- 697
- 698
- 699
- 700
- 701

#### 703 Figures

704



# 705 **Figure 1. The IBI Algorithm. A.** IBI uses a bipartite BN to model the probabilistic

706	relationships from genomic Variants to Traits. $V$ nodes denote variants and $T$ nodes denote
707	traits; the arcs denote the predictive relationships from $V$ to $T$ with only one assumed
708	predictive variant being evaluated at a time indicated by the solid arc. B. Using the entire
709	dataset (D) or population to evaluate the association between a particular genomic variant
710	and a trait, GWAS methods output the p-value while the Bayesian method uses the marginal
711	likelihood ( $M_s$ ) and global posterior probability (GPP). <b>C.</b> Based on the value of a particular
712	variant $V_s$ , IBI partitions the whole population into two subpopulations, $D^{V_s=1}$ and $D^{V_s=0}$ , and
713	derives the subpopulation-specific marginals, $M_S^1$ and $M_r^0$ , using $V_s$ and $V_r$ as the assumed
714	cause specifically. The overall marginal $M_{s,r}$ and the individual-specific posterior probability,
715	$P(V_s^h \to T_i^h   D)$ for the SNP $V_s$ can be further derived. <b>D.</b> Pseudo code for the IBI algorithm.



Figure 2. A Bayesian method for GWAS analysis. A. The p-value ranks and  $M_s$  or GPP ranks are the same or similar for the top 189 SNPs selected by  $M_s$  or p-value ranking. B. The p-values were very much negatively correlated with the  $M_s$  values of the top 189 SNPs selected by  $M_s$  or p-value ranking. C. The p-values were very much negatively correlated with the global posterior probabilities (GPP) of the top 189 SNPs selected by  $M_s$  or p-value ranking.

724

- 725
- 726



727





743Figure 4. HTN patient coverage. A. The 16 unique GWAS SNPs ranked by p-values were744plotted against the cumulative number of HTN patients explained. B. The 25 unique IBI745SNPs ranked by  $M_{s,r}$  were plotted against the cumulative number of HTN patients explained.746The number of HTN patients covered by each of these SNPs can be derived by taking the747difference of the two adjacent cumulative numbers of explained HTN patients as showed for748rs13265032 covering 425 HTN patients. C. Histogram of the individualized posterior749probability of the top-1 SNP assigned by IBI to each of the 930 HTN patient.



Figure 5. ROC curves for predicting hypertension from top SNPs. Top 1 SNP (A, B, C) and top 3 SNPs (D, E, F) selected by GWAS (p-value ranking), IBI ( $M_{s,r}$  ranking) or randomly were used to calculate the genetic risk scores for each test patient, which were further used to derive the AUROC for predicting hypertension. For these two experiments, random SNPs have AUROC as 0.50 (Top 1/3 SNP; (A, D); GWAS-selected top SNPs have AUROC as 0.55 (B, E); IBI-selected top SNPs have AUROC as 0.59 for top 1 SNP and 0.60 for top 3 SNPs.